<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="364733">
  <stage>Registered</stage>
  <submitdate>5/08/2013</submitdate>
  <approvaldate>8/08/2013</approvaldate>
  <actrnumber>ACTRN12613000885796</actrnumber>
  <trial_identification>
    <studytitle>Xuanju Compound Capsule VS Terazosin in treatment of chronic prostatitis: a Prospective Randomized Controlled Trial</studytitle>
    <scientifictitle>Xuanju Compound Capsule compared with Terazosin in treatment of patients with chronic prostatitis: evaluation of symptom and NIH-CPSI </scientifictitle>
    <utrn>U1111-1146-3373 </utrn>
    <trialacronym />
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>chronic prostatitis</healthcondition>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Alternative and Complementary Medicine</conditioncode1>
      <conditioncode2>Other alternative and complementary medicine</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions> xuanju compound capsule in treatment of chronic prostatitis; 1.26mg oral administrated 3 times daily for 12 weeks; keeping diary for taking medicine</interventions>
    <comparator>Terazosin in treatment of chronic prostatitis; 2mg oral tablet once daily for 12 weeks; keeping diary for taking medicine</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>chronic prostatis symptoms assessed by NIH-CPSI score</outcome>
      <timepoint>3 months later after treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>immune function asseessed by serum CD4,CD8,IgA, IgM, IgG, IL-2,IL-8, TNF-a</outcome>
      <timepoint>3 months later after teatment</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>VAS assessed by pain tools</outcome>
      <timepoint>3 months later after teatment</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1.consistent with chronic non-bacterial prostatitis diagnosis, duration &gt;3 months;
2.aged 18 to 50 years old;
3.Chronic Prostatitis Symptom Index (NIH-CPSI) &gt;11 points;
4.immune dysfunction; (recommended results based on pre-select several sensitive indicators);
5.voluntarily signed informed consent.
</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>50</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Males</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1.except for I,II, IV type of prostatitis patients;
2.pelvic area pain, voiding dysfunction patients, benign prostatic hyperplasia, prostate cancer, testicular epididymis and spermatic cord disease, overactive bladder, neurogenic bladder, interstitial cystitis, bladder gland , sexually transmitted diseases, bladder cancer, anorectal disease, lumbar disease, central and peripheral neuropathy;
3.local pain as the main manifestation of the patients, specifically by the ureteral stones, bladder stones, inguinal hernia, pubic inflammation, varicocele, epididymitis, colorectal disease, caused by low back myofascial go far;
4.severe neurosis, mental illness;
5.past month have used drugs for treating chronic prostatitis or other relevant treatment;
6.associated with cardiovascular, cerebrovascular, liver and kidney and hematopoietic system in patients with severe primary disease, liver function ALT and / or AST&gt; 1.5 times the upper limit of normal persons;
7.allergies, or known of the test drug ingredients or terazosin drugs have allergies;;
8.participating in the other clinical trials in a past month;
9.researchers consider it inappropriate to participate in clinical trials.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>1/02/2014</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>1000</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Not yet recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>China</country>
      <state />
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Democratic People's Republic Of</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>zhou tie </primarysponsorname>
    <primarysponsoraddress>shanghai changhai hospital;changhai road 168#, shanghai , China;200433</primarysponsoraddress>
    <primarysponsorcountry>China</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>shanghai changhai hospital</fundingname>
      <fundingaddress>changhai road 168#, shanghai , China;200433</fundingaddress>
      <fundingcountry>China</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>sun yinghao </sponsorname>
      <sponsoraddress>shanghai changhai hospital;changhai road 168#, shanghai , China;200433</sponsoraddress>
      <sponsorcountry>China</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Immune dysfunction has been thought of to be involved in patients with chronic prostatitis. Thus we use xuanju compound capsule, a traditional chinese drug, to treat chronic prostatitis and terazosin used in control group. XUANJU capsule is a kind of chinese traditional drug and has the role in immunoregulation. If xuanju capsule indeed improve the symptom of patients with chronic prostatitis, will give strong evidence to demonstrate the important role of immune regulation in treatment of chronic prostatitis.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>changhai hospital ethic committee</ethicname>
      <ethicaddress>changhai road 168#, shanghai , China;200433</ethicaddress>
      <ethicapprovaldate>29/07/2013</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>China</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Prof</title>
      <name>zhou tie</name>
      <address>shanghai changhai hospital;changhai road 168#, shanghai , China;200433</address>
      <phone>+86 2113918360523</phone>
      <fax />
      <email>wenzhoutie@163.com</email>
      <country>China</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>zhou tie</name>
      <address>shanghai changhai hospital;changhai road 168#, shanghai , China;200433</address>
      <phone>+86 2113918360523</phone>
      <fax />
      <email>wenzhoutie@163.com</email>
      <country>China</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>zhou tie</name>
      <address>shanghai changhai hospital;changhai road 168#, shanghai , China;200433</address>
      <phone>+86 2113918360523</phone>
      <fax />
      <email>wenzhoutie@163.com</email>
      <country>China</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Prof</title>
      <name>zhou tie</name>
      <address>shanghai changhai hospital;changhai road 168#, shanghai , China;200433</address>
      <phone />
      <fax />
      <email />
      <country>China</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>